Older people are increasing in number worldwide and they are affected by neurodegenerative disorders. Tauopathies are neurodegenerative disorders that involve diseases such as progressive supranuclear palsy (PSP), frontotemporal dementia linked to chromosome 17 (FTD-17), corticobasal degeneration, and Alzheimer's disease (AD) among others. Other neurodegenerative disorders such as Parkinson's disease is characterized for inclusion denominated as Lewis bodies conformed by hyperphosphorylated alpha-synuclein protein (α-syn). However, there are some neurodegenerative disorders that overlap each other such as dementia with Lewy bodies (DLB), Lewy body variant of AD and Parkinson's disease with dementia (PDD). Moreover, there is an increase in the number of patients of PD with dementia and patients with AD with Lewy body's inclusions in post mortem samples. Thus, we find pertinent to discuss both covalent and noncovalent inhibitors targeting alpha-synuclein and tau.